Published in J Card Fail on November 14, 2009
Relation between hemoglobin a(1c) and outcomes in heart failure patients with and without diabetes mellitus. Am J Cardiol (2012) 1.51
Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr (2013) 1.31
Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care (2010) 1.00
AMP-activated protein kinase regulates E3 ligases in rodent heart. Circ Res (2011) 0.99
Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med (2017) 0.88
Heart failure in the diabetic population - pathophysiology, diagnosis and management. Arch Med Sci (2014) 0.86
Metformin in Diabetic Patients with Heart Failure: Safe and Effective? Curr Cardiovasc Risk Rep (2013) 0.85
Metformin use in patients with diabetes mellitus and heart failure: friend or foe? J Card Fail (2010) 0.81
After avandia: the use of antidiabetic drugs in patients with heart failure. Tex Heart Inst J (2012) 0.81
Changes in labelling for metformin use in patients with type 2 diabetes and heart failure: documented safety outweighs theoretical risks. Open Med (2011) 0.79
The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. Heart Fail Rev (2016) 0.76
Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications. Drug Des Devel Ther (2015) 0.75
Treatment strategies for the prevention of heart failure. Curr Heart Fail Rep (2013) 0.75
[Diabetes and heart failure]. Herz (2010) 0.75
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2009) 12.34
Diabetes and cardiovascular disease. The Framingham study. JAMA (1979) 11.95
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA (2002) 8.81
Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med (2001) 4.81
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care (2005) 4.78
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95
Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. N Engl J Med (1996) 3.07
Glycemic control and heart failure among adult patients with diabetes. Circulation (2001) 2.99
The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care (2004) 2.79
Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol (1997) 2.35
Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res (2008) 2.19
An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J (2006) 2.11
Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation (2005) 1.83
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol (2009) 1.69
Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol (1996) 1.55
The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol (2007) 1.45
AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) (2009) 1.43
Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol (2004) 1.38
Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ (2007) 1.34
The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care (2004) 1.29
Metformin in heart failure. Diabetes Care (2007) 1.29
Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation (2009) 1.19
The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail (2008) 1.17
Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J (2008) 1.17
Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials (2009) 1.05
The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev (2005) 1.04
Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Saf (2005) 0.92
Metformin: an antihyperglycemic agent for treatment of type II diabetes. Ann Pharmacother (1996) 0.86
Mortality remains high for outpatient transplant candidates with prolonged (>6 months) waiting list time. J Am Coll Cardiol (1999) 0.83
Metformin therapy in patients with type 2 diabetes complicated by heart failure. Am Heart J (2007) 0.81
Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA (2010) 6.91
Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA (2013) 5.05
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA (2007) 4.89
Epidemiology and risk profile of heart failure. Nat Rev Cardiol (2010) 4.88
Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA (2006) 4.30
Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol (2005) 4.26
Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation (2008) 4.00
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Survival advantages of obesity in dialysis patients. Am J Clin Nutr (2005) 3.75
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation (2009) 3.43
Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol (2008) 3.35
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Body mass index and mortality in heart failure: a meta-analysis. Am Heart J (2008) 3.25
Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol (2012) 3.24
Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol (2004) 3.08
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA (2012) 3.07
Use of aldosterone antagonists in heart failure. JAMA (2009) 3.00
Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol (2002) 2.97
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol (2013) 2.89
Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol (2010) 2.86
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J (2007) 2.80
High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail (2007) 2.75
The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res (2004) 2.72
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol (2005) 2.71
Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med (2012) 2.64
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol (2006) 2.59
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
Racial and ethnic differences in the treatment of acute myocardial infarction: findings from the Get With the Guidelines-Coronary Artery Disease program. Circulation (2010) 2.53
An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol (2013) 2.47
Cardiac troponin and outcome in acute heart failure. N Engl J Med (2008) 2.41
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol (2008) 2.39
Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation (2010) 2.32
Sex differences in medical care and early death after acute myocardial infarction. Circulation (2008) 2.17
Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. JAMA (2013) 2.17
Four-variable risk model in men and women with heart failure. Circ Heart Fail (2013) 2.14
Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol (2009) 2.14
Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol (2005) 2.11
An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J (2006) 2.11
Visual assessment of brain magnetic resonance imaging detects injury to cognitive regulatory sites in patients with heart failure. J Card Fail (2013) 2.07
Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J (2008) 2.06
Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol (2007) 2.06
B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: insights from the Acute Decompensated Heart Failure National Registry. Am Heart J (2012) 2.04
Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation (2012) 2.03
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure. Circ Heart Fail (2011) 1.99
Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med (2007) 1.98
An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension (2013) 1.95
Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. Circ Heart Fail (2009) 1.95
Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? J Am Coll Cardiol (2011) 1.92
Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation (2003) 1.90
Waist circumference, body mass index, and survival in systolic heart failure: the obesity paradox revisited. J Card Fail (2011) 1.90
The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med (2009) 1.89
Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. J Am Coll Cardiol (2009) 1.88
A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction. Circ Cardiovasc Qual Outcomes (2009) 1.86
Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care (2007) 1.82
Use of cardiac resynchronization therapy in patients hospitalized with heart failure. Circulation (2008) 1.81
Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol (2009) 1.81
Use of two recipient lists for adults requiring heart transplantation. J Thorac Cardiovasc Surg (2003) 1.78
Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke. Stroke (2014) 1.76
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J (2011) 1.72
Association of patient case-mix adjustment, hospital process performance rankings, and eligibility for financial incentives. JAMA (2008) 1.69
Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol (2003) 1.67
The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. Heart (2010) 1.67
Regional brain gray matter loss in heart failure. J Appl Physiol (1985) (2003) 1.67
Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines-Stroke Program. Circulation (2010) 1.66
American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers. Circulation (2013) 1.66
Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol (2012) 1.65
Payment source, quality of care, and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol (2011) 1.65
Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol (2012) 1.64
Association between direct measures of body composition and prognostic factors in chronic heart failure. Mayo Clin Proc (2010) 1.63
The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol (2007) 1.63
Incremental value of clinical data beyond claims data in predicting 30-day outcomes after heart failure hospitalization. Circ Cardiovasc Qual Outcomes (2010) 1.63
Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. Med Care (2010) 1.62
Mode and mechanisms of death after orthotopic heart transplantation. Heart Rhythm (2009) 1.60
Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke (2011) 1.60
ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 1.58
National efforts to improve door-to-balloon time results from the Door-to-Balloon Alliance. J Am Coll Cardiol (2009) 1.57